Adamis Pharmaceuticals Corporation STOCK REPURCHASE AGREEMENT
Adamis
Pharmaceuticals Corporation
THIS STOCK REPURCHASE AGREEMENT
(this “Agreement”) is
made as of the 3rd day of
November 2008 by and between Adamis
Pharmaceuticals Corporation, a Delaware corporation (the “Company”),
and Xxxxxx Xxxxxxx (“Stockholder”).
Whereas, the Stockholder owns six
hundred seventy thousand seven hundred and fifty (670,750) shares of the Common
Stock of the Company (the “Stock”)
which he purchased at $0.001 per share (the “Per-Share
Purchase Price”); and
Whereas, the Stockholder became
an employee of the Company on September 1, 2007 “the Vesting
Commencement Date”; and
Whereas,
on or about October 28, 2008, the Company declined its right of first refusal
and approved the sale and transfer from Xxxxxxx Xxxxx to Purchaser an aggregate
two hundred thousand (200,000) shares of the Common Stock of the Company subject
to the terms and conditions set forth in the Stock Purchase Agreement dated
April 17, 2007; and
Whereas, the Stockholder agrees
to designate all the eight hundred seventy thousand seven hundred and fifty
(870,750) shares of the Common Stock as being "Repurchasable
Stock;" and
Whereas, the Stockholder executed
a Stock
Repurchase Agreement with the Company effective as of the 25th day of
September, 2008; and
Whereas, the Company wishes to
replace the previous Stock
Repurchase Agreement effective September 25, 2008 with this Stock
Repurchase Agreement;
Now,
THEREFORE, IT IS AGREED
between the parties as follows:
1.
REPURCHASE OPTIONS.
In addition to any restrictions imposed by the Bylaws of the Company, the
Company has two independent options to repurchase the Repurchasable Stock:
Performance; and Time-Based (collectively referred to herein as the "Repurchase
Options"). Each reference to Repurchasable Stock in this Agreement shall
mean the number of shares of Repurchasable Stock after giving effect to any
adjustment in the aggregate number of shares of Repurchasable Stock as a result
of the exercise of any of the preceding Repurchase Options. The Repurchase
Options may be triggered by one of the following Repurchase Events ("Repurchase
Event"):
(i)
Adamis Laboratories, Inc. reports financial results in any two sequential fiscal
quarters that meet both of the two criteria set forth below:
(1) net
revenue is in excess of $3.5 million in the two sequential quarters,
and
1.
(2) operating
profit before product development expenses of at least 15% of
net revenue during the same two sequential quarters.
For
purposes of this section 1.(a)(i), net revenue shall be determined in accordance
with Generally Accepted Accounting Principles and defined as gross product sales
reduced by returns, discounts, allowances and royalties. Operating profit shall
be determined in accordance with Generally Accepted Accounting Principles and
defined as net sales less cost of goods sold less sales, general and
administrative expenses, depreciation, and amortization. It specifically
excludes interest extraordinary expenses and product development
expenses.
(ii) the
volume weighted average price of the Company’s common stock is at an average
price in excess of $1.00 per share, as reported by the exchange on which the
Company's common stock is then trading, during twenty (20) consecutive trading
days.
If the
criteria have not been met, the Company shall be entitled to repurchase the
fraction of Stockholder's aggregate shares of Repurchasable Stock determined by
dividing (1) the difference between (A) $3,500,000 and (B) the amount of net
revenue reported in the quarter ending June 30, 2010, by (2)
$3,500,000.
For
purposes of illustrating the effect of the Performance Repurchase Option, assume
that an individual holds 1,000,000 shares of Repurchasable Stock and that for
the quarter ending on June 30, 2010 the reported net revenue of the Company is
$3,000,000. The Company would have the right to repurchase 142,857 shares of
Repurchasable Stock (i.e., $500,000/$3,500,000 X 1,000,000). Stockholder would
then hold 857,143 shares of Repurchasable Stock.
(b) Time-Based Repurchase Option.
A Repurchase Event will also occur if the Stockholder’s relationship with
the Company or any of its Affiliates terminates for any reason (including death
or disability), or for no reason, with or without cause, such that after such
termination Stockholder is no longer an employee of, or consultant to, the
Company or any of its Affiliates. For purposes of the preceding sentence, a
party shall be deemed to control an entity if such party directly or indirectly
owns more than 50% of the voting interests in such entity.
(i) One
hundred percent (100%) of the Repurchasable Stock shall initially be subject to
the Time-Based Repurchase Option. On the first anniversary of the Vesting
Commencement Date, one-third (1/3) of the Time-Based Repurchase Option shares,
or such lesser amount as is determined after giving effect to any exercise of
the Performance Repurchase Option, of the Repurchasable Stock shall lapse and be
released from the Time-Based Repurchase Option. Thereafter, an additional
one-third (1/3) of the Repurchasable Stock shall be released from the Time-Based
Repurchase Option on the second anniversary of the Vesting Commencement Date,
and an additional one-third (1/3) of the Repurchasable Stock shall be released
from the Time-Based Repurchase Option on the third anniversary of the Vesting
Commencement Date.
(ii) In
the event of Stockholder's death or Disability (as defined below), the
Time-Based Repurchase Option shall lapse with respect to all of Stockholder's
shares of Repurchasable Stock, but remain subject to the Performance Repurchase
Options.
2.
(iii) In
the event of a Corporate Transaction (as defined below), the Repurchase Options
shall lapse with respect to all of Stockholder's shares of Repurchasable
Stock. A “Corporate
Transaction” shall mean either (a) an Acquisition; or (b) an Asset
Transfer where: “Acquisition”
shall mean (A) any consolidation or merger of the Company with or into
any other corporation or other entity or person, or any other corporate
reorganization, in which the capital stock of the Company immediately prior to
such consolidation, merger or reorganization, represents less than 50% of the
voting power of the surviving entity (or, if the surviving entity is a wholly
owned subsidiary, its parent) immediately after such consolidation, merger or
reorganization; or (B) any transaction or series of related transactions to
which the Company is a party in which in excess of fifty percent (50%) of the
Company's voting power is transferred; provided that an Acquisition shall not
include (x) any consolidation or merger effected exclusively to change the
domicile of the Company, or (y) any transaction or series of transactions
principally for bona fide equity financing purposes in which cash is received by
the Company or any successor or indebtedness of the Company is cancelled or
converted or a combination thereof; and “Asset Transfer”
shall mean a sale, lease, exclusive license or other disposition of all
or substantially all of the assets of the Company.
(iv) For
purposes of the Time-Based Repurchase Option, “Cause”
shall mean misconduct,
including:
(1) the
willful failure of Stockholder to follow the good faith directions of the
Company's Board of Directors (the “Adamis
Board”), or any other Company personnel to whom Stockholder reports after
written notice thereof and a ten (10) day opportunity to cure;
(2) any
act by Stockholder of fraud or dishonesty, misappropriation or embezzlement, or
willful misconduct or gross negligence in connection with the performance of any
of Stockholder's duties to or for the Company, as reasonably and in good faith
determined by the Adamis Board;
(3) a
material breach by Stockholder of this Agreement or his employment agreement
with the Company (the “Employment
Agreement”), the
lawful written policies of the Company, any contractual or legal duty to the
Company or any of its Affiliates, or any guidelines or procedures of the Company
provided such policies, guidelines and procedures have been provided to or
otherwise made available to the Stockholder, after written notice thereof from
the Company and a ten (10) day opportunity to cure in the event that such breach
was not willful;
(4) the
conviction of Stockholder of a felony or a crime involving moral turpitude
(including pleading guilty or no contest to such crime), whether or not such
felony or crime was committed in connection with the business of the Company or
its Affiliates; or
(5) any
act of Stockholder which injures or could reasonably be expected to injure the
reputation, business or business relationships of the Company or its
Affiliates.
(v) For
purposes of the Time-Based Repurchase Option, “Good Cause”
shall mean:
(1) the
Company commits a material breach of its obligations under the Employment
Agreement and fails to cure such breach within twenty (20) business days
following receipt of notice of such breach; or
3.
(2) Stockholder’s
principal office is relocated 100 or more miles from its present location,
except for required travel by Stockholder on the Company’s or any of its
Affiliates’ business.
(vi) For
purposes of the Time-Based Repurchase Option, “Disability”
shall mean the inability of a person, in the opinion of a qualified
physician acceptable to the Company, to perform the major duties of that
person’s position with the Company or any of its Affiliates because of the
sickness or injury of the person.
2. EXERCISE OF
REPURCHASE OPTIONS.
(a) If a Repurchase Event, as
defined above, occurs, the Company shall have an irrevocable option, for a
period of ninety (90) days after said Repurchase Event (or such longer period as
may be agreed to by the Company and the Stockholder) to repurchase from
Stockholder (or Stockholder's personal representative, as the case may be) at
$0.001 per share (“Option
Price”), up
to but not exceeding the number of shares of Repurchasable Stock subject to that
Repurchase Option as of the date of such Repurchase Event. Stockholder hereby acknowledges that the Company has no
obligation, either now or in the future, to repurchase any of the shares of
Stock, whether vested or unvested, at any time.
(b) The Repurchase Options
shall be exercised by written notice signed by an officer of the Company or by
any assignee or assignees of the Company and delivered or mailed as provided in
Section 13(a). Such notice shall identify the number of shares of Repurchasable
Stock to be purchased and shall notify Stockholder of the time, place and date
for settlement of such purchase, which shall be scheduled by the Company within
the applicable term of the Repurchase Option set forth in Section 1 above. The
Company shall be entitled to pay for any shares of Repurchasable Stock purchased
pursuant to its Repurchase Option in cash or by offset against any indebtedness
owing to the Company by Stockholder, or by a combination of both, as determined
by the Company in its sole discretion. Upon delivery of such notice and payment
of the purchase price in any of the ways described above, the Company shall
become the legal and beneficial owner of the Repurchasable Stock being
repurchased and all rights and interest therein or related thereto, and the
Company shall have the right to transfer to its own name the Repurchasable Stock
being repurchased by the Company or take any other action with respect to such
Repurchasable Stock, without further action by Stockholder.
4.
4. [RESERVED
TO RETAIN NUMBERING]
(a) If
any payment or benefit Stockholder would receive pursuant to a Corporate
Transaction from the Company, its Affiliates or otherwise (“Payment”)
would (i) constitute a “parachute payment” within the meaning of Section 280G of
the Internal Revenue Code of 1986, as amended (the “Code”), and (ii) but for
this sentence, be subject to the excise tax imposed by Section 4999 of the Code
(the “Excise
Tax”), then
such Payment shall be reduced to the Reduced Amount. The “Reduced Amount”
shall be either (x) the largest portion of the Payment that would result
in no portion of the Payment being subject to the Excise Tax or (y) the largest
portion, up to and including the total, of the Payment, whichever amount, after
taking into account all applicable federal, state and local employment taxes,
income taxes, and the Excise Tax (all computed at the highest applicable
marginal rate), results in Stockholder's receipt, on an after-tax basis, of the
greater amount of the Payment notwithstanding that all or some portion of the
Payment may be subject to the Excise Tax. If a reduction in payments or benefits
constituting "parachute payments" is necessary so that the Payment equals the
Reduced Amount, reduction shall occur in the following order unless Stockholder
elects in writing a different order (provided, however, that such
election shall be subject to Company approval if made on or after the date on
which the event that triggers the Payment occurs): reduction of cash payments;
cancellation of accelerated vesting of stock awards; reduction of employee
benefits. In the event that acceleration of vesting of stock award compensation
is to be reduced, such acceleration of vesting shall be cancelled in the reverse
order of the date of grant of Stockholder's stock awards unless Stockholder
elects in writing a different order for cancellation.
(b) The
accounting firm engaged by the Company for general audit purposes as of the day
prior to the effective date of the Corporate Transaction shall perform the
foregoing calculations. If the accounting firm so engaged by the Company is
serving as accountant or auditor for the individual, entity or group effecting
the Corporate Transaction, the Company shall appoint a nationally recognized
accounting firm to make the determinations required hereunder. The Company shall
bear all expenses with respect to the determinations by such accounting firm
required to be made hereunder.
(c) The
accounting firm engaged to make the determinations hereunder shall provide its
calculations, together with detailed supporting documentation, to the Company
and Stockholder within fifteen (15) calendar days after the date on which
Stockholder's right to a Payment is triggered (if requested at that time by the
Company or Stockholder) or such other time as requested by the Company or
Stockholder. If the accounting firm determines that no Excise Tax is payable
with respect to a Payment, it shall furnish the Company and Stockholder with an
opinion reasonably acceptable to Stockholder that no Excise Tax will be imposed
with respect to such Payment. Any good faith determinations of the accounting
firm made hereunder shall be final, binding and conclusive upon the Company and
Stockholder.
5.
9. RESTRICTIVE LEGENDS. All
certificates representing the Stock shall have endorsed thereon legends in
substantially the following forms (in addition to any other legend which may be
required by other agreements between the parties hereto):
(a) “THE
SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO A RIGHT OF FIRST REFUSAL
OPTION IN FAVOR OF THE COMPANY AND/OR ITS ASSIGNEE(S), AS PROVIDED IN THE
COMPANY’S BYLAWS.”
(b) "THE
SHARES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE
SECURITIES ACT OF 1933 AS AMENDED. THEY MAY NOT BE SOLD, OFFERED FOR SALE,
PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT AS
TO THE SECURITIES UNDER SAID ACT OR AN OPINION OF COUNSEL SATISFACTORY TO THE
COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED."
(c) Any
additional legend required by the Company's Bylaws, as such may be amended from
time to time.
(d) Any
legend required by appropriate blue sky officials.
(e) Any
legend required to enforce the provisions of Section 10 hereof
6.
(f) With
respect to the Repurchasable Stock only: "THE SHARES REPRESENTED BY THIS
CERTIFICATE ARE SUBJECT TO CERTAIN OPTIONS AND RESTRICTIONS SET FORTH IN AN
AGREEMENT BETWEEN THE COMPANY AND THE REGISTERED HOLDER, OR HIS PREDECESSOR IN
INTEREST, A COPY OF WHICH IS ON FILE AT THE PRINCIPAL OFFICE OF THIS COMPANY.
ANY TRANSFER OR ATTEMPTED TRANSFER OF ANY SHARES SUBJECT TO SUCH OPTION IS VOID
WITHOUT THE PRIOR EXPRESS WRITTEN CONSENT OF THE ISSUER OF THESE
SHARES."
7.
(d) Governing Law; Venue. This
Agreement shall be governed by and construed in accordance with the laws of the
State of Delaware. The parties agree that any action brought by either party to
interpret or enforce any provision of this Agreement shall be brought in, and
each party agrees to, and does hereby, submit to the jurisdiction and venue of,
the appropriate state or federal court for the district encompassing the
Company's principal place of business.
reasonably
be necessary to carry out and consummate this Agreement as soon as practicable,
and to take whatever steps may be necessary to obtain any governmental approval
in connection with or otherwise qualify the issuance of the securities that are
the subject of this Agreement.
8.
(k) California Corporate Securities
Law. THE SALE OF THE SECURITIES WHICH ARE THE SUBJECT OF THIS AGREEMENT
HAS NOT BEEN QUALIFIED WITH THE COMMISSIONER OF CORPORATIONS OF THE STATE OF
CALIFORNIA AND THE ISSUANCE OF SUCH SECURITIES OR THE PAYMENT OR RECEIPT OF ANY
PART OF THE CONSIDERATION THEREFOR PRIOR TO SUCH QUALIFICATION OR IN THE ABSENCE
OF AN EXEMPTION FROM SUCH QUALIFICATION IS UNLAWFUL. PRIOR TO ACCEPTANCE OF SUCH
CONSIDERATION BY THE COMPANY, THE RIGHTS OF ALL PARTIES TO THIS AGREEMENT ARE
EXPRESSLY CONDITIONED UPON SUCH QUALIFICATION BEING OBTAINED OR AN EXEMPTION
FROM SUCH QUALIFICATION BEING AVAILABLE.
9.
In Witness
Whereof, the parties hereto have executed this Agreement as of the day
and year first above written.
Adamis
Pharmaceuticals corporation
|
|
By:
|
/s/
Xxxxxx X. Xxxxx
|
Title:
|
CEO
|
Address:
|
0000
Xxx Xxx Xxxxxxx Xxxx, #000
Xxx
Xxx, XX 00000
|
Stockholder
acknowledges and agrees that the vesting of Stock pursuant to Section 1
hereof is earned only by continuing service as an employee or consultant at the
will of the Company or its Affiliates. Stockholder further acknowledges and
agrees that nothing in this agreement shall confer upon Stockholder any right
with respect to continuation of such employment or consulting relationship with
the Company or its Affiliates, nor shall it interfere in any way with
Stockholder’s right or the right of the Company or its Affiliates to terminate
Stockholder’s employment or consulting relationship at any time, with or without
cause.
Stockholder
acknowledges and agrees that Stockholder must bear the economic risk of this
investment indefinitely unless the repurchasable Stock is registered pursuant to
the Securities Act or an exemption from registration is available, and that the
Company has no obligation to repurchase such repurchasable Stock. Stockholder
further acknowledges that any risk related to the fluctuation in the value of
the repurchasable stock from and after the date hereof, including any losses to
Stockholder as a result of Company’s exercise of any of its repurchase options
pursuant to Section 1, shall be borne by Stockholder.
Stockholder
acknowledges that Stockholder has had an opportunity to consult Stockholder’s
own tax, legal and financial Advisors regarding the acquisition of common stock
under the Stock Purchase Agreement and the restrictions relating to such stock
under this Agreement.
Stockholder
acknowledges and agrees that in making the decision to acquire the common stock
under the Stock Purchase Agreement Stockholder has not relied on any statement,
whether written or oral, regarding the subject matter hereof, except as
expressly provided in the Stock Purchase Agreement and herein and in the
attachments and exhibits thereto and hereto.
Stockholder:
|
/s/ Xxxxxx Xxxxxxx |
Xxxxxx
Xxxxxxx
|
10.
Exhibit
A
RELEASE
AGREEMENT
I
understand that my position with Adamis Pharmaceuticals Corporation. (the "Company")
terminated effective (the "Separation
Date"). The Company has agreed that if I
choose to sign this Release, the Company will extend to me certain benefits
(minus the standard withholdings and deductions, if applicable) pursuant to the
terms of the Stock Repurchase Agreement (the "Agreement')
entered into as of November 3, 2008, between myself and the Company, and
any agreements incorporated therein by reference. I understand that I am not
entitled to such benefits unless I sign this Release. I understand that,
regardless of whether I sign this Release, the Company will pay me all of my
accrued salary and vacation through the Separation Date, to which I am entitled
by law.
In
consideration for the benefits I am receiving under the Agreement, I hereby
release the Company and its officers, directors, agents, attorneys, employees,
stockholders, and Affiliates from any and all claims, liabilities, demands,
causes of action, attorneys' fees, damages, or obligations of every kind and
nature, whether they are now known or unknown, arising at any time prior to the
date I sign this Release. This general release includes, but is not limited to:
all federal and state statutory and common law claims, claims related to my
employment or the termination of my employment or related to breach of contract,
tort, wrongful termination, discrimination, wages or benefits, or claims for any
form of equity or compensation. Notwithstanding the release in the preceding
sentence, I am not releasing any right of indemnification I may have for any
liabilities arising from my actions within the course and scope of my employment
with the Company.
In
releasing claims unknown to me at present, I am waiving all rights and benefits
under Section 1542 of the California Civil Code, and any law or legal principle
of similar effect in any jurisdiction: "A general release does not extend to
claims which the creditor does not know or suspect to exist in his favor at
the time of executing the release, which if known by him must have materially
affected his settlement with the debtor."
If I am
forty (40) years of age or older as of the Separation Date, I acknowledge that I
am knowingly and voluntarily waiving and releasing any rights I may have under
the federal Age Discrimination in Employment Act of 1967, as amended ("ADEA"). I
also acknowledge that the consideration given for the waiver in the above
paragraph is in addition to anything of value to which I was already entitled. I
have been advised by this writing, as required by the ADEA that: (a) my waiver
and release do not apply to any claims that may arise after my signing of this
Release; (b) I should consult with an attorney prior to executing this Release;
(c) I have twenty-one (21) days within which to consider this Release (although
I may choose to voluntarily execute this Release earlier); (d) I have seven (7)
days following the execution of this release to revoke the Release; and (e) this
Release will not be effective until the eighth day after this Release has been
signed both by me and by the Company ("Effective
Date").
Agreed:
Xxxxxx
Xxxxxxx
|
11.
ADAMIS
PHARMACEUTICALS CORPORATION.
|
|
By:
|
|
Name:
|
|
Title:
|
12.